Avelumab Shows Promise as Frontline Immunotherapy Alternative in NSCLC – OncLive
|
Avelumab Shows Promise as Frontline Immunotherapy Alternative in NSCLC
OncLive Study author Claire Verschraegen, MD, who presented the findings at the WCLC, believes that with further research, avelumab could be used as an alternative immunotherapy option in lung cancer, either as a single-agent or in combination with other agents. |
